obesity management
Mar 12, 2024
BeiGene’s BRUKINSA Gets FDA Accelerated Approval; GSK’s Positive Results in DREAMM-8 Phase III; Sandoz’s Denosumab Biosimilars FDA Approved; Terns Pharma’s TERN-701 Receives Orphan Drug Designation; Wegovy® Approved in US for Overweight Cardiovascular Risk; Travere Therapeutics Submits sNDA for FILSPARI IgAN Full Approval
BeiGene Receives FDA Accelerated Approval for BRUKINSA in Relapsed/Refractory Follicular Lymphoma BeiGene, Ltd., has declared that the FDA has provided accelerated approval for BRUKINSA® (zanubrutinib) to be used in treating adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), when used alo...
Read More...
Apr 19, 2023
Body Contouring Devices: Understanding the Key Factors Determining the Market Growth and Evolving Trends
Body Contouring is a highly evolving concept in the field of cosmetic dermatology, and the demand for these devices to improve the body's appearance is growing at an immense rate. Some of the products have demonstrated excellent clinical efficacy and safety. With the rising awareness regarding noninvasive and minim...
Read More...
Jun 17, 2022
Obesity: A Worldwide Pandemic with Advancing Management Options
Obesity is a chronic health condition that leads to abnormal or excessive fat accumulation or adipose tissue in the body that presents a health risk. It is an imbalance between calories ingested and calories burned. The factors responsible for the causes of obesity include heredity, a sedentary lifestyle, excessive...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
